Inaxaplin for the treatment of APOL1-associated kidney disease

Nature Reviews Nephrology, Published online: 27 April 2023; doi:10.1038/s41581-023-00721-0APOL1 risk variants are associated with an increased risk of chronic kidney disease. Findings from a new study demonstrate that a small molecule, inaxaplin, inhibits APOL1 channel function; furthermore, inaxaplin reduced proteinuria in patients with focal segmental glomerulosclerosis and two APOL1 risk variants.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research